Literature DB >> 10440695

Intratumoral heterogeneity of DNA content in renal cell carcinoma and its prognostic significance.

J L Ruiz-Cerdá1, M Hernández, A Sempere, J E O'Connor, B F Kimler, F Jiménez-Cruz.   

Abstract

BACKGROUND: A multiple sampling study was performed on 124 specimens of renal cell carcinomas to analyze the consistency and reliability of DNA measurements. The authors investigated intratumoral DNA heterogeneity and its role as a adverse prognostic factor for disease progression.
METHODS: DNA content was analyzed by flow cytometry on three different samples of the same tumor. The Cronbach alpha coefficient was used to assess the reliability and a Cox proportional hazards model was used to test the effect of DNA ploidy heterogeneity on time of disease progression.
RESULTS: The agreement among the DNA ploidy samples was high. The number of aneuploid findings increased significantly with the number of samples analyzed. The presence of non-diploid cell populations was a significant adverse predictive value for disease progression. However, the authors were unable to demonstrate that intratumoral heterogeneity DNA content had any influence on the biological behavior of the tumor.
CONCLUSIONS: Determination of DNA ploidy based on single samples may be inaccurate. Spatial variation in DNA ploidy is a feature of renal cell carcinoma; however, its biologic significance remains to be demonstrated. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440695     DOI: 10.1002/(sici)1097-0142(19990815)86:4<664::aid-cncr16>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?

Authors:  Rosalie Fisher; James Larkin; Charles Swanton
Journal:  Front Oncol       Date:  2012-05-18       Impact factor: 6.244

2.  A non-diploid DNA status is linked to poor prognosis in renal cell cancer.

Authors:  Franziska Büscheck; Christoph Fraune; Martina Kluth; Maximilian Lennartz; Ronald Simon; Claudia Hube-Magg; Christian Morlock; Silvano Barbieri; Carolin Wahl; Christian Eichelberg; Christina Möller-Koop; Doris Höflmayer; Corinna Wittmer; Waldemar Wilczak; Guido Sauter; Margit Fisch; Till Eichenauer; Michael Rink
Journal:  World J Urol       Date:  2020-05-02       Impact factor: 4.226

3.  Intratumoral Genomic Heterogeneity May Hinder Precision Medicine Strategies in Patients with Serous Ovarian Carcinoma.

Authors:  Kohei Nakamura; Eriko Aimono; Shigeki Tanishima; Mitsuho Imai; Akiko Kawano Nagatsuma; Hideyuki Hayashi; Yuki Yoshimura; Kentaro Nakayama; Satoru Kyo; Hiroshi Nishihara
Journal:  Diagnostics (Basel)       Date:  2020-04-03

4.  LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway.

Authors:  Ran Cui; Guangming Cao; Huimin Bai; Zhenyu Zhang
Journal:  Cancer Cell Int       Date:  2019-07-29       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.